ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
ArriVent BioPharma announced that its Phase 3 FURVENT clinical trial evaluating firmonertinib monotherapy in first-line treatment of locally advanced or metastatic non-squamous NSCLC patients with EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival by blinded independent central review. Although secondary…